Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Cameco Corporation Q1 2026 Earnings Call - Nuclear Execution Replaces Aspiration as U.S. Reactor Pipeline Accelerates
Cameco’s Q1 2026 results reflect disciplined execution amid a structural shift in nuclear policy, with management emphasizing that durable demand growth requires sustained supply discipline and long-t...
- Management reaffirmed full-year 2026 guidance, citing Q1 performance as consistent with expectations and driven by timing and pricing rather than fundamental shifts.
- U.S. Department of Commerce and Department of Energy are advancing parallel pathways for AP1000 deployment, targeting up to 20 reactors with a combined $80 billion commitment.
- Westinghouse reported improved adjusted EBITDA despite a net loss, reflecting normal project variability and amortization of acquisition-related intangibles.
- +7 more takeaways
Alkermes Q1 2026 Earnings Call - Avadel Acquisition Drives Revenue Beat and Expands Orexin Pipeline
Alkermes delivered a strong first quarter of 2026, with proprietary net sales jumping 38% year-over-year to $338.1 million, fueled by solid demand across its psychiatry and addiction franchises and th...
- Alkermes completed the acquisition of Avadel Pharmaceuticals in mid-February, integrating LUMRYZ into its portfolio and establishing an immediate commercial presence in sleep medicine ahead of its lead orexin-2 receptor agonist candidate, alixorexton.
- First-quarter proprietary net sales surged 38% year-over-year to $338.1 million, beating prior expectations, driven by strong performance in psychiatry (ARISTADA, LYBALVI) and addiction (VIVITROL), plus six weeks of LUMRYZ revenue.
- LUMRYZ generated $72 million in net revenue for the quarter, with approximately $39.5 million recorded in the first six weeks post-acquisition; the company exited Q1 with about 3,600 patients on therapy and expects $315-$335 million in full-year LUMRYZ sales.
- +7 more takeaways
inTEST Corporation Q1 2026 Earnings Call - Raised FY26 Guidance on Diverse Demand and Operating Leverage
inTEST delivered a strong Q1 2026, with revenue of $33.9 million and adjusted EBITDA of $3.2 million, both beating guidance. The company raised its full-year 2026 revenue guidance to $130-$135 million...
- Q1 2026 revenue reached $33.9 million, up 27% year-over-year, beating the upper end of guidance.
- Adjusted EBITDA came in at $3.2 million with a 9.3% margin, exceeding expectations and driven by favorable product mix and operating leverage.
- Full-year 2026 revenue guidance was raised to $130-$135 million, reflecting diversified demand and improved market conditions.
- +7 more takeaways
Leidos Q1 2026 Earnings Call - Raised 2026 Guidance by $500 Million Following Accelerant Entrust Acquisition
Leidos delivered a robust Q1 2026 start, posting 4% year-over-year revenue growth to $4.4 billion and maintaining a 14% adjusted EBITDA margin. The catalyst for the quarter was the immediate close of ...
- Raised 2026 revenue guidance by $500 million to $18.0-$18.4 billion, driven immediately by the accretive nature of the Entrust acquisition.
- Q1 2026 revenue reached $4.4 billion, up 4% year-over-year, with adjusted EBITDA margin holding steady at a robust 14%.
- Non-GAAP diluted EPS grew 5% to $3.13, supported by higher EBITDA, a lower effective tax rate, and share buybacks.
- +7 more takeaways
Gartner Q1 2026 Earnings Call - Contract Value Acceleration and Margin Expansion Drive EPS Growth
Gartner delivered a strong Q1 2026, beating expectations on revenue, EBITDA, and free cash flow, while accelerating contract value growth to 1% year-over-year. The company raised its full-year guidanc...
- Q1 2026 contract value grew 1% year-over-year, accelerating from Q4 2025, with ex-federal government growth reaching 3.5%.
- Full-year EBITDA guidance raised to at least $1.545 billion, reflecting a 24.1% margin and a $30 million increase from prior estimates.
- Adjusted EPS of $3.32 beat expectations, driven by 11% year-over-year growth and a 4% reduction in share count through $535 million in buybacks.
- +7 more takeaways
Onity Group Q1 2026 Earnings Call - Origination Surge Masks Servicing Headwinds
Onity Group delivered a mixed first quarter, with origination volume and revenue surging more than 4x year-over-year as falling rates triggered a refinancing boom. However, the company posted a $6 mil...
- Revenue grew 26% year-over-year, driven by a 4x surge in consumer direct origination volume and strong subservicing additions of 94%.
- Adjusted pre-tax income fell to a $6 million loss, contrasting sharply with $34 million in origination profit, as servicing income dropped $54 million.
- MSR runoff tripled year-over-year to $99 million, primarily due to higher prepayments from borrower rate sensitivity and lingering FHA delinquencies.
- +9 more takeaways
Repligen Corporation Q1 2026 Earnings Call - Strategic Reset Drives Margin Expansion and China Reacceleration
Repligen reported a strong Q1 2026 with 11% organic revenue growth and 160 basis points of adjusted operating margin expansion, beating expectations on both top and bottom lines. Management raised ful...
- Q1 2026 revenue reached $194 million, reflecting 15% reported and 11% organic growth, with adjusted operating margin expanding 160 basis points year-over-year.
- Full-year adjusted EPS guidance was raised to $1.97-$2.05, up $0.04 at both ends, driven by strong Q1 performance, Polymem divestiture, and operating expense discipline.
- Organic revenue guidance for 2026 remains 9%-13%, with gross margin expansion expected to accelerate to 110-160 basis points, supported by favorable product mix and volume leverage.
- +9 more takeaways
AdaptHealth Corp Q1 2026 Earnings Call - Largest HME Patient Transition Delivers Revenue Beat, EBITDA Misses on Labor Costs
AdaptHealth delivered a strong revenue beat in Q1 2026, driven by the accelerated rollout of its new capitated contract and solid organic growth across all four segments. The company successfully tran...
- Q1 2026 net revenue of $819.8 million grew 5.4% year-over-year, exceeding guidance by approximately $22 million, with organic growth accelerating to 9.1%.
- The company completed the largest patient transition in HME history, moving hundreds of thousands of patients to a new capitated contract ahead of schedule and establishing 35 de novo locations.
- Capitated revenue surged to $74.9 million, reflecting a seven-fold increase in covered membership to approximately 15 million, now accounting for 9.2% of total consolidated net revenue.
- +7 more takeaways
PayPal Q1 2026 Earnings Call - New CEO Lores Unveils $1.5B Cost Cuts and Three-Unit Reorg
PayPal’s new CEO Enrique Lores used his first earnings call to lay out a stark turnaround plan. The company is splitting into three focused units—Checkout, Consumer Financial Services (Venmo), and Pay...
- New CEO Enrique Lores outlines a three-unit organizational structure: Checkout Solutions, Consumer Financial Services (Venmo), and Payment Services (Braintree/Crypto), replacing the previous customer-segment model to eliminate decision-making bottlenecks.
- PayPal commits to at least $1.5 billion in gross run-rate cost savings over the next two to three years, driven by organizational simplification and aggressive AI adoption across operations and technology development.
- Lores admits the company over-indexed on merchants in recent years and is now rebalancing investment toward the consumer side to drive habituation, loyalty, and lifetime value through financial services and BNPL.
- +9 more takeaways
Palladyne AI Q1 2026 Earnings Call - Decentralized Swarming Tech Gains Traction Amid Defense Spending Surge
Palladyne AI reported a 107% year-over-year revenue increase to $3.5 million in Q1 2026, driven by post-acquisition manufacturing and engineering services. The company navigated a federal government s...
- Revenue surged 107% year-over-year to $3.5 million, with $1.7 million from product manufacturing and $1.8 million from engineering services.
- Backlog increased to $17 million, up from $13.5 million, reflecting $7 million in new contract awards net of revenue recognized.
- Full-year 2026 revenue guidance reiterated at $24 million to $27 million, implying 357%-415% growth from 2025.
- +7 more takeaways